Skip to main content
Log in

Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2

References

  1. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336.

    Article  CAS  Google Scholar 

  2. Marcucci G, Mrozek K, Bloomfield CD . Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005; 12: 68–75.

    Article  CAS  Google Scholar 

  3. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.

    Article  CAS  Google Scholar 

  4. Gallagher RE . Dueling mutations in normal karyotype AML. Blood 2005; 106: 3681.

    Article  CAS  Google Scholar 

  5. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006 (E-pub ahead of print).

  6. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740–3746.

    Article  Google Scholar 

Download references

Acknowledgements

We thank all participating investigators from the GOELAMS protocol, Jessica Zuman-Rossi for valuable help and Veronique Della Valle for assistance in the initial steps of this work. This work was supported by ‘l'Association Laurette Fugain’ (www.laurettefugain.org).

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to C Récher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bardet, V., Costa, L., Elie, C. et al. Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype. Leukemia 20, 1644–1646 (2006). https://doi.org/10.1038/sj.leu.2404294

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404294

  • Springer Nature Limited

Navigation